Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CeNeRx to initiate Phase II depression trial
This milestone is based on the positive results of the Tyrima Phase I program reported earlier in 2008 and the recent completion of Pet brain imaging studies showing
This milestone is based on the positive results of the Tyrima Phase I program reported earlier in 2008 and the recent completion of Pet brain imaging studies showing
The clinical trial was designed with an initial accelerated titration design followed by a standard dose escalation schema. The trial has completed the accelerated titration design component and
The partnership will help drive development of Metabolon’s pre-diabetes diagnostic products as well as provide valuable data for insulin resistance and diabetes-related research. Metabolon will be analyzing samples
This launch follows the recent FDA approval of Vyvanse to treat attention deficit hyperactivity disorder (ADHD) in the adult population. Vyvanse is now available in US pharmacies nationwide
The preliminary results of the study suggest that IRX-2 is safe and well tolerated and survival data show promising results when compared to historical controls. In this multi-center
Mr Scott joins North American Scientific from his role as CFO at Alsius, a medical device company focused on temperature control of patients in the critical care arena.
Core Essence Orthopaedics’s products include the Securus knotless suture anchor system, initially targeted at arthroscopic rotator cuff repair. Other key products are the nABLE percutaneous suture management system,
The transaction is subject to certain approvals and closing conditions. The company anticipates closing this transaction by the end of the third quarter of 2008. In conjunction with
Xanodyne’s Zipsor is a proprietary immediate release liquid-filled soft gelatin capsule containing 25mg of diclofenac potassium for oral administration. Zipsor is a unique formulation designed for rapid and
HPN-100 is a pro-drug of phenylbutryrate and a pre-pro-drug of phenylacetic acid, the active moiety of Buphenyl, the only therapy currently FDA-approved as adjunctive therapy for the chronic